FIELD: pharmacology.
SUBSTANCE: invention relates to a number of other similar specific compounds, pharmaceutical compositions, comprising these compounds and their application to obtain a drug to inhibit the STAT3 and/or STAT5 activity or to treat cancer, where the cancer cells contain activated STAT3 or STAT5.
,
,
,
.
EFFECT: preparation of a drug for STAT3 and STAT5 activity inhibition or for cancer treatment where the cancer cells contain activated STAT3 or STAT5.
20 cl, 21 dwg, 6 tbl, 76 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CAFFEIC ACID BIOLOGICALLY AVAILABLE FOR ORAL USE, ASSOCIATED WITH ANTITUMOUR MEDICINAL AGENTS | 2007 |
|
RU2456265C2 |
| TREATING OR PREVENTING PROLIFERATIVE CONDITIONS | 2010 |
|
RU2705548C2 |
| SULPHONAMIDE COMPOUNDS AND USE THEREOF AS STAT5 INHIBITORS | 2015 |
|
RU2707094C2 |
| THERAPEUTIC AGENTS AIMED AT SHORTENED PROTEINS OF ADENOMATOUS POLYPOSIS COLI (APC) | 2014 |
|
RU2727516C2 |
| AMYLOID-BINDING AGENTS | 2010 |
|
RU2517174C2 |
| TAXANE DERIVATIVES, METHOD OF THEIR SYNTHESIS, PHARMACEUTICAL COMPOSITION AND METHOD OF TREATMENT | 1994 |
|
RU2137764C1 |
| PHENYLCARBAMATES AND USE THEREOF AS ENZYME INHIBITORS OF HYDROLASES OF FATTY ACID AMIDES (FAAH) AND DOPAMINE RECEPTOR D3 (D3DR) MODULATORS | 2014 |
|
RU2693457C2 |
| SPIRO OXINDOLE MDM2 ANTAGONISTS | 2010 |
|
RU2553269C2 |
| ENZYME-ACTIVATING COMPOUNDS AND COMPOSITIONS | 2013 |
|
RU2652989C2 |
| ANALOGUES OF TAMANDARINE AND DIDEMNINE AND METHODS FOR THEIR PREPARING AND USING | 2001 |
|
RU2323000C2 |
